Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

The Prognostic Value of Histopathologic Lesions in Native Kidney Biopsy Specimens: Results from the Boston Kidney Biopsy Cohort Study.

Srivastava A, Palsson R, Kaze AD, Chen ME, Palacios P, Sabbisetti V, Betensky RA, Steinman TI, Thadhani RI, McMahon GM, Stillman IE, Rennke HG, Waikar SS.

J Am Soc Nephrol. 2018 Aug;29(8):2213-2224. doi: 10.1681/ASN.2017121260. Epub 2018 Jun 4.

2.

Longitudinal Assessment of Left Ventricular Mass in Autosomal Dominant Polycystic Kidney Disease.

Dad T, Abebe KZ, Bae KT, Comer D, Torres VE, Czarnecki PG, Schrier RW, Steinman TI, Moore CG, Chapman AB, Kaya D, Tao C, Braun WE, Winklhofer FT, Brosnahan G, Hogan MC, Miskulin DC, Rahbari Oskoui F, Flessner MF, Perrone RD.

Kidney Int Rep. 2018 Jan 6;3(3):619-624. doi: 10.1016/j.ekir.2017.12.011. eCollection 2018 May.

3.

Determinants of Progression in Early Autosomal Dominant Polycystic Kidney Disease: Is it Blood Pressure or Renin-Angiotensin-Aldosterone-System Blockade?

Brosnahan GM, Abebe KZ, Moore CG, Bae KT, Braun WE, Chapman AB, Flessner MF, Harris PC, Hogan MC, Perrone RD, Rahbari-Oskoui FF, Steinman TI, Torres VE, The Halt Pkd Investigators.

Curr Hypertens Rev. 2018;14(1):39-47. doi: 10.2174/1573402114666180322110209.

4.

Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD Trials.

Brosnahan GM, Abebe KZ, Moore CG, Rahbari-Oskoui FF, Bae KT, Grantham JJ, Schrier RW, Braun WE, Chapman AB, Flessner MF, Harris PC, Hogan MC, Perrone RD, Miskulin DC, Steinman TI, Torres VE; HALT-PKD Trial Investigators.

Am J Kidney Dis. 2018 May;71(5):666-676. doi: 10.1053/j.ajkd.2017.10.023. Epub 2018 Jan 3.

5.

ADPKD Progression in Patients With No Apparent Family History and No Mutation Detected by Sanger Sequencing.

Braun WE, Abebe KZ, Brosnahan G, Patterson CG, Chapman AB, Harris PC, Hogan MC, Perrone RD, Torres VE, Miskulin DC, Steinman TI, Winklhofer FT, Rahbari-Oskoui FF, Czarnecki PG, Bae KT, Grantham JJ, Flessner MF, Schrier RW.

Am J Kidney Dis. 2018 Feb;71(2):294-296. doi: 10.1053/j.ajkd.2017.09.008. Epub 2017 Dec 2. No abstract available.

6.

Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease.

Nowak KL, You Z, Gitomer B, Brosnahan G, Torres VE, Chapman AB, Perrone RD, Steinman TI, Abebe KZ, Rahbari-Oskoui FF, Yu ASL, Harris PC, Bae KT, Hogan M, Miskulin D, Chonchol M.

J Am Soc Nephrol. 2018 Feb;29(2):571-578. doi: 10.1681/ASN.2017070819. Epub 2017 Nov 8.

7.

Fibroblast Growth Factor 23 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease.

Chonchol M, Gitomer B, Isakova T, Cai X, Salusky I, Pereira R, Abebe K, Torres V, Steinman TI, Grantham JJ, Chapman AB, Schrier RW, Wolf M.

Clin J Am Soc Nephrol. 2017 Sep 7;12(9):1461-1469. doi: 10.2215/CJN.12821216. Epub 2017 Jul 13.

8.

Effect of Statin Therapy on the Progression of Autosomal Dominant Polycystic Kidney Disease. A Secondary Analysis of the HALT PKD Trials.

Brosnahan GM, Abebe KZ, Rahbari-Oskoui FF, Patterson CG, Bae KT, Schrier RW, Braun WE, Chapman AB, Flessner MF, Harris PC, Perrone RD, Steinman TI, Torres VE; HALT PKD Investigators.

Curr Hypertens Rev. 2017;13(2):109-120. doi: 10.2174/1573402113666170427142815.

9.

Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease.

Torres VE, Abebe KZ, Schrier RW, Perrone RD, Chapman AB, Yu AS, Braun WE, Steinman TI, Brosnahan G, Hogan MC, Rahbari FF, Grantham JJ, Bae KT, Moore CG, Flessner MF.

Kidney Int. 2017 Feb;91(2):493-500. doi: 10.1016/j.kint.2016.10.018. Epub 2016 Dec 16.

10.

TECHNOLOGY AND THE FUTURE OF KIDNEY CARE.

Freedman BS, Zeidel ML, Steinman TI.

Nephrol News Issues. 2016 Nov;30(12):24-28.

PMID:
30645802
11.

Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial.

Irazabal MV, Abebe KZ, Bae KT, Perrone RD, Chapman AB, Schrier RW, Yu AS, Braun WE, Steinman TI, Harris PC, Flessner MF, Torres VE; HALT Investigators.

Nephrol Dial Transplant. 2017 Nov 1;32(11):1857-1865. doi: 10.1093/ndt/gfw294.

12.

Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney Disease.

Heyer CM, Sundsbak JL, Abebe KZ, Chapman AB, Torres VE, Grantham JJ, Bae KT, Schrier RW, Perrone RD, Braun WE, Steinman TI, Mrug M, Yu AS, Brosnahan G, Hopp K, Irazabal MV, Bennett WM, Flessner MF, Moore CG, Landsittel D, Harris PC; HALT PKD and CRISP Investigators.

J Am Soc Nephrol. 2016 Sep;27(9):2872-84. doi: 10.1681/ASN.2015050583. Epub 2016 Jan 28.

13.

Modelling kidney disease with CRISPR-mutant kidney organoids derived from human pluripotent epiblast spheroids.

Freedman BS, Brooks CR, Lam AQ, Fu H, Morizane R, Agrawal V, Saad AF, Li MK, Hughes MR, Werff RV, Peters DT, Lu J, Baccei A, Siedlecki AM, Valerius MT, Musunuru K, McNagny KM, Steinman TI, Zhou J, Lerou PH, Bonventre JV.

Nat Commun. 2015 Oct 23;6:8715. doi: 10.1038/ncomms9715.

14.

iPS cell technology: Future impact on renal care.

Freedman BS, Steinman TI.

Nephrol News Issues. 2015 Aug;29(9):18, 20-1.

15.

Closeout of the HALT-PKD trials.

Moore CG, Spillane S, Simon G, Maxwell B, Rahbari-Oskoui FF, Braun WE, Chapman AB, Schrier RW, Torres VE, Perrone RD, Steinman TI, Brosnahan G, Czarnecki PG, Harris PC, Miskulin DC, Flessner MF, Bae KT, Abebe KZ, Hogan MC.

Contemp Clin Trials. 2015 Sep;44:48-55. doi: 10.1016/j.cct.2015.07.017. Epub 2015 Jul 29.

16.

Therapeutic advances in the treatment of polycystic kidney disease.

Riella C, Czarnecki PG, Steinman TI.

Nephron Clin Pract. 2014;128(3-4):297-302. doi: 10.1159/000368244. Epub 2015 Jan 6. Review.

17.

Blood pressure in early autosomal dominant polycystic kidney disease.

Schrier RW, Abebe KZ, Perrone RD, Torres VE, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czarnecki PG, Hogan MC, Miskulin DC, Rahbari-Oskoui FF, Grantham JJ, Harris PC, Flessner MF, Bae KT, Moore CG, Chapman AB; HALT-PKD Trial Investigators.

N Engl J Med. 2014 Dec 11;371(24):2255-66. doi: 10.1056/NEJMoa1402685. Epub 2014 Nov 15.

18.

Angiotensin blockade in late autosomal dominant polycystic kidney disease.

Torres VE, Abebe KZ, Chapman AB, Schrier RW, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czarnecki PG, Hogan MC, Miskulin DC, Rahbari-Oskoui FF, Grantham JJ, Harris PC, Flessner MF, Moore CG, Perrone RD; HALT-PKD Trial Investigators.

N Engl J Med. 2014 Dec 11;371(24):2267-76. doi: 10.1056/NEJMoa1402686. Epub 2014 Nov 15.

19.

Role of sodium restriction in recurrent stone formers with hyperoxaluria.

Garg N, Steinman TI.

Am J Kidney Dis. 2014 Sep;64(3):478. doi: 10.1053/j.ajkd.2014.03.023. No abstract available.

PMID:
25150857
20.

Liver involvement in early autosomal-dominant polycystic kidney disease.

Hogan MC, Abebe K, Torres VE, Chapman AB, Bae KT, Tao C, Sun H, Perrone RD, Steinman TI, Braun W, Winklhofer FT, Miskulin DC, Rahbari-Oskoui F, Brosnahan G, Masoumi A, Karpov IO, Spillane S, Flessner M, Moore CG, Schrier RW.

Clin Gastroenterol Hepatol. 2015 Jan;13(1):155-64.e6. doi: 10.1016/j.cgh.2014.07.051. Epub 2014 Aug 9.

21.

Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study.

Miskulin DC, Abebe KZ, Chapman AB, Perrone RD, Steinman TI, Torres VE, Bae KT, Braun W, Winklhofer FT, Hogan MC, Rahbari-Oskoui F, Moore CG, Flessner MF, Schrier RW; HALT-PKD Study.

Am J Kidney Dis. 2014 Feb;63(2):214-26. doi: 10.1053/j.ajkd.2013.08.017. Epub 2013 Nov 1.

22.

Polycystic kidney disease: new horizons and therapeutic frontiers.

Czarnecki PG, Steinman TI.

Minerva Urol Nefrol. 2013 Mar;65(1):61-8. Review.

PMID:
23538311
23.

The older patient with end-stage renal disease: is chronic dialysis the best option?

Steinman TI.

Semin Dial. 2012 Nov-Dec;25(6):602-5. doi: 10.1111/sdi.12035.

PMID:
23173889
24.

Dialysis at a crossroads--Part II: A call for action.

Parker TF 3rd, Straube BM, Nissenson A, Hakim RM, Steinman TI, Glassock RJ.

Clin J Am Soc Nephrol. 2012 Jun;7(6):1026-32. doi: 10.2215/CJN.11381111. Epub 2012 Apr 12.

25.

Polycystic kidney disease: a 2011 update.

Steinman TI.

Curr Opin Nephrol Hypertens. 2012 Mar;21(2):189-94. doi: 10.1097/MNH.0b013e32835011a7. Review.

PMID:
22274800
26.

Analysis of baseline parameters in the HALT polycystic kidney disease trials.

Torres VE, Chapman AB, Perrone RD, Bae KT, Abebe KZ, Bost JE, Miskulin DC, Steinman TI, Braun WE, Winklhofer FT, Hogan MC, Oskoui FR, Kelleher C, Masoumi A, Glockner J, Halin NJ, Martin DR, Remer E, Patel N, Pedrosa I, Wetzel LH, Thompson PA, Miller JP, Meyers CM, Schrier RW; HALT PKD Study Group.

Kidney Int. 2012 Mar;81(6):577-85. doi: 10.1038/ki.2011.411. Epub 2011 Dec 28.

27.

Cardiac magnetic resonance assessment of left ventricular mass in autosomal dominant polycystic kidney disease.

Perrone RD, Abebe KZ, Schrier RW, Chapman AB, Torres VE, Bost J, Kaya D, Miskulin DC, Steinman TI, Braun W, Winklhofer FT, Hogan MC, Rahbari-Oskoui F, Kelleher C, Masoumi A, Glockner J, Halin NJ, Martin D, Remer E, Patel N, Pedrosa I, Wetzel LH, Thompson PA, Miller JP, Bae KT; HALT PKD Study Group, Meyers CM.

Clin J Am Soc Nephrol. 2011 Oct;6(10):2508-15. doi: 10.2215/CJN.04610511. Epub 2011 Sep 8.

28.

Changing the models and measurements of dialysis care.

Parker TF, Steinman TI.

Nephrol News Issues. 2010 Mar;24(3):35-9, 43-4. No abstract available.

PMID:
20364496
29.

The HALT polycystic kidney disease trials: design and implementation.

Chapman AB, Torres VE, Perrone RD, Steinman TI, Bae KT, Miller JP, Miskulin DC, Rahbari Oskoui F, Masoumi A, Hogan MC, Winklhofer FT, Braun W, Thompson PA, Meyers CM, Kelleher C, Schrier RW.

Clin J Am Soc Nephrol. 2010 Jan;5(1):102-9. doi: 10.2215/CJN.04310709.

30.

Conclusions, consensus, and directions for the future.

Parker TF 3rd, Glassock RJ, Steinman TI.

Clin J Am Soc Nephrol. 2009 Dec;4 Suppl 1:S139-44. doi: 10.2215/CJN.05820809. No abstract available.

31.

Introduction to the proceedings.

Steinman TI, Parker TF 3rd.

Clin J Am Soc Nephrol. 2009 Dec;4 Suppl 1:S1. doi: 10.2215/CJN.05830809. No abstract available.

32.

Low and therapeutic doses of antidepressants are associated with similar response in the context of multimodal treatment of pain.

Bajwa ZH, Simopoulos TT, Pal J, Kraemer JJ, Chopra P, Nagda JV, Najib U, Celestin J, Sial K, Ahmad B, Warfield C, Steinman TI, Wootton J.

Pain Physician. 2009 Sep-Oct;12(5):893-900.

33.

Can the fractional excretion of uric acid distinguish the etiology of hyponatremia in patients taking diuretics?

Steinman TI.

Nat Clin Pract Endocrinol Metab. 2008 Nov;4(11):602-3. doi: 10.1038/ncpendmet0973. Epub 2008 Sep 23. No abstract available.

PMID:
18813214
34.

Case records of the Massachusetts General Hospital. Case 27-2008. A 64-year-old man with abdominal pain, nausea, and an elevated level of serum creatinine.

Steinman TI, Samir AE, Cornell LD.

N Engl J Med. 2008 Aug 28;359(9):951-60. doi: 10.1056/NEJMcpc0804600. No abstract available.

PMID:
18753652
35.

Reducing morbidity and mortality in incident hemodialysis patients with an early intervention program.

Steinman TI.

Nat Clin Pract Nephrol. 2008 May;4(5):248-9. doi: 10.1038/ncpneph0747. Epub 2008 Jan 29. No abstract available.

PMID:
18227819
36.

Renal and cardiac effects of antihypertensive treatment with ramipril versus metoprolol in autosomal dominant polycystic kidney disease.

Steinman TI.

Nephrol Dial Transplant. 2008 Feb;23(2):431-3. Epub 2007 Dec 8. No abstract available.

PMID:
18065782
37.

Polycystic kidney disease: a new perspective from the beginning.

Steinman TI.

Kidney Int. 2005 Nov;68(5):2398-9. No abstract available.

38.

Ending dialysis: new perspectives on end-of-life considerations.

Cohen LM, Steinman TI, Robinson WM.

Med Ethics (Burlingt Mass). 2004 Spring;11(2):5-8. No abstract available.

PMID:
15841574
39.

The many faces of HIV nephropathy: results of the disease and consequences of treatment.

Lam C, Stillman IE, Steinman TI.

J Nephrol. 2005 Jan-Feb;18(1):106-10.

PMID:
15772932
40.

Hypercalcemia due to excess 1,25-dihydroxyvitamin D in Crohn's disease.

Tuohy KA, Steinman TI.

Am J Kidney Dis. 2005 Jan;45(1):e3-6.

PMID:
15696436
41.
42.

Pain patterns in patients with polycystic kidney disease.

Bajwa ZH, Sial KA, Malik AB, Steinman TI.

Kidney Int. 2004 Oct;66(4):1561-9.

43.

Using guidelines to improve care of patients with chronic kidney disease.

Steinman TI.

Am J Manag Care. 2004 Jul;10(7 Pt 1):413-4. No abstract available.

44.

A dangerous argument against organ donation.

Steinman TI.

Natl Cathol Bioeth Q. 2002 Autumn;2(3):473-8. No abstract available.

PMID:
12854601
45.

L-carnitine use in dialysis patients: is national coverage for supplementation justified? What were CMS regulators thinking--or were they?

Steinman TI, Nissenson AR, Glassock RJ, Dickmeyer J, Mattern WD, Parker TF 3rd, Hull AR.

Nephrol News Issues. 2003 Apr;17(5):28-30, 32-4, 36 passim. Review.

PMID:
12715624
46.

Changing the operating structure in.

Bednar B, Steinman TI, Street J.

Nephrol News Issues. 2002 Jul;16(8):25-8.

PMID:
12154551
47.
48.

A 57-year-old woman with gross hematuria and bilateral renal masses: an unusual presentation of acute interstitial nephritis.

Mix TC, Stillman IE, McNamara A, Steinman TI.

Am J Kidney Dis. 2002 Mar;39(3):653-8. No abstract available.

PMID:
11877586
49.

Pain management in polycystic kidney disease.

Bajwa ZH, Gupta S, Warfield CA, Steinman TI.

Kidney Int. 2001 Nov;60(5):1631-44. Review.

50.

Guidelines for the referral and management of patients eligible for solid organ transplantation.

Steinman TI, Becker BN, Frost AE, Olthoff KM, Smart FW, Suki WN, Wilkinson AH; Clinical Practice Committee, American Society of Transplantation.

Transplantation. 2001 May 15;71(9):1189-204.

PMID:
11397947

Supplemental Content

Loading ...
Support Center